Takeover in Wuppertal: Aicuris Anti-Infective Cures AG, which specializes in active ingredients for infectious diseases, is being acquired by Japanese pharmaceutical company Asahi Kasei for almost €800 million (around US$920 million). The company, founded by former Bayer employees Helga Rübsamen-Schaeff and Holger Zimmermann using substances from Bayer, had obtained its own approval and is currently in late-stage clinical development with active ingredients that are currently being presented with positive data at scientific conferences.
Boehringer steps back from MASH programm as OSE restructure its pipeline
Latest NewsFrench biotech OSE Immunotherapeutics is narrowing its ambitions to just two late-stage programs after a one–two hit: AbbVie backing away from an inflammation partnership and Boehringer Ingelheim halting the liver-disease leg of a separate collaboration following a mid-stage failure. The company now says it will concentrate resources on its cancer vaccine Tedopi and its IL-7 receptor antibody lusvertikimab, while pausing or ending several earlier-stage efforts to conserve cash and push toward near-term clinical catalysts.
The Bridge to your success
slider, Sponsored PublicationsCustomized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product.
NVision visualizes metabolics at work and expands to the Cambridge Innovation Cluster
Latest NewsQuantum computers? While most people have heard that their massively parallel data processing could open up an entirely new dimension of information technology, tangible real-world examples remain scarce. NVision Imaging Technologies in Ulm has been active in the field for years and has now developed a visible and practical innovation in metabolic imaging: real-time MRI. Leading academic institutions have already expressed strong interest.
Sitryx adds another BigPharma and partners with Boehringer Ingelheim in autoimmune push
Latest NewsOxford-based immunology specialist Sitryx has entered into a new agreement with Boehringer Ingelheim aimed at advancing a novel small-molecule programme in autoimmune and inflammatory disease. The deal could be worth USD500 million in total, but the breakdown of the payments in upfront and milestones was not disclosed in detail.
Japan’s Asahi Kasei buys antiviral specialist Aicuris in €780 million deal
Latest NewsTakeover in Wuppertal: Aicuris Anti-Infective Cures AG, which specializes in active ingredients for infectious diseases, is being acquired by Japanese pharmaceutical company Asahi Kasei for almost €800 million (around US$920 million). The company, founded by former Bayer employees Helga Rübsamen-Schaeff and Holger Zimmermann using substances from Bayer, had obtained its own approval and is currently in late-stage clinical development with active ingredients that are currently being presented with positive data at scientific conferences.
argenx expands VYVGART into ocular MG as profitability signals franchise maturity
Latest Newsargenx delivered two significant updates on the same day: positive Phase 3 results in ocular myasthenia gravis (oMG) and its first full year of operating profitability. Together, the announcements show a company expanding its lead medicine into a new patient population while doing so from a position of financial strength.
Novo Nordisk partners with MIT spinout Vivtex in deal worth up to $2.1bn to advance oral biologics for obesity
Latest NewsDenmark’s Novo Nordisk has signed a collaboration with Boston-based Vivtex Corporation to develop next-generation oral biologic medicines for obesity, diabetes and associated metabolic diseases. Vivtex is eligible to receive upfront payments, research funding and milestone payments totalling up to $2.1 billion (approximately €1.78bn), as well as tiered royalties on net sales of any resulting products.
GSK buys 35Pharma for $950m, targeting next-generation pulmonary hypertension therapy and the TGF-β superfamily
Latest NewsGSK will pay $950m for Montreal-based 35Pharma to secure HS235, an investigational activin signalling inhibitor that has completed Phase I trials in healthy volunteers and is set to begin studies in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
Skin in the AI game: Beiersdorf Ventures invests in AI biology platform Turbine
Latest NewsAs a co-investor in the USD 25 million Series B round, Beiersdorf AG is signalling that artificial intelligence is becoming strategically important for skin research. The Hamburg-based group is participating through its venture unit in the AI biotech Turbine, founded in Budapest and now also headquartered in London.
Brainomix extends Series C to £18.8m as Oxford AI imaging spinout pushes into the US
Latest NewsOxford-based Brainomix has added £4.8 million (approximately $6.5m/€5.5m) to its Series C financing, bringing the total round to £18.8 million ($25.4m/€21.5m) and providing fresh capital to accelerate the US rollout of its AI-powered imaging platforms for stroke and lung fibrosis.